What Do You Need for Injection

Firstly, you need a 100-ml insulin syringe with a long needle. The peculiarity of this syringe is that it quickly and reliably delivers somatropin to your body. Such syringe is used for diabetes mellitus, for the rapid transport of protein and amino acids. Secondly, you need to buy water for injection, which is sold in almost every pharmacy.

Thirdly, in addition to insulin syringes, you need normal 5-ml ones, with a long needle too. This syringe is required for filling with water for injection and reconstituting growth hormone in this water. In addition, you should buy cotton wool, cotton pads, alcohol for skin disinfection and solution-containing vials in advance.

Correct reconstitution of growth hormone.

For proper growth hormone reconstitution, you need water for injection. Thanks to it, you can store the solution for 14 calendar days.

Step 1. Fill the 5-ml syringe with water for injection. In order to avoid getting water on the powder, inject the contents of the syringe into the growth hormone-containing vial very slowly, so that it flows down the wall.

Step 2. Even more carefully, avoiding stirring and shaking, begin to rotate the vial until the contents are completely dissolved. To reconstitute growth hormone, one or two milliliters are enough per vial containing somatropin.

Calculate the dose of growth hormone

The dose for unreconstituted growth hormone is 10 units per vial. Thus, when reconstituting the contents in 1 ml of water, and if you need a single administration of 3 units, divide the contents into 3 approximately equal parts.

Injection guidelines

Reconstituted growth hormone should be injected into the belly fat roll. This is approximately 6-10 cm to either side of the navel. It is worth noting that in this area there are extremely painful points, and they are located differently for each person. Unfortunately, these points can only be found by trial and error. We recommend changing the injection site from time to time, because by injecting somatropin into the same place regularly, you may face the breakdown of fat depots at the injection site. Over time, the subcutaneous fat will break down and a dent will appear. Wash your hands with soap and water before injecting, and then wipe them with alcohol. Treat the injection site and a large area around. Do not forget to disinfect the vial! Fill the syringe with the solution smoothly and slowly to avoid oxygen entering your solution

Injection

Now, you’re ready to inject growth hormone into your abdominal area; stretch the skin in the selected place with one hand, if you are right-handed – with your left hand, and vice versa. Pierce the skin with the needle at a 45-degree angle smoothly and rapidly. Press the plunger of the syringe slowly. Do not remove the syringe immediately after injecting growth hormone; wait 10-15 seconds to avoid leakage of growth hormone.

Best time to inject

Somatropin should be injected on an empty stomach, or 5-6 hours after a meal. To ensure the maximum absorption effect and a beneficial effect on all cells of your body, do not eat within an hour, and preferably two after injection. Actually, the growth hormone is the most active in the human body at low blood sugar level.

It is necessary to take intervals of 4 or 5 hours between the injections of growth hormone. The injection schedule will help you keep control over the improvement of your body; do not ignore it and always keep it. During the course of injections, you need to follow a high-protein diet, which will help growth hormone to give you all its beneficial properties.

The protein calculation should be as follows: 3 grams per 1 kg of your body weight, as well as a very small amount of fast carbohydrates. You can combine injections and anabolic steroids. If you are young, inject growth hormone in the morning upon waking up. If you are middle-aged or elderly, and are affected by the ageing, give injections before going to bed. The second injection should be given 5-6 hours after the first one either in the morning or in the afternoon, depending on your age, lifestyle and individual characteristics of the body.

Transportation of Growth Hormone

Transportation of liquid growth hormone is easy, but in compliance with cold chain standards; just store it in a dark and cool place. For very comfortable transportation, there are special (small, of course) travel cases, for example, iCool weekender. They are suitable for storage: vials or pens (insulin, growth hormones, L-thyroxine, polyarthritis medications) helps to keep your medicine between 2°C-8°C for 12 hours. The iCool bag uses a new generation of chemical gel pack that makes very little condensation and cools longer than ice packs. This allows diabetic patients or those using temperature-sensitive medications to transport their medications for a longer cooling period. There is enough space inside to store everything you need for injections both in reconstituted and unreconstituted form.

Here are a few practices to store growth hormone properly. Keep out of reach of children and pets. Keep it in the same place every day to avoid losing. Do not store somatropin in the freezer or near the freezer compartment. If you store the hormone in the refrigerator, make sure it does not fall out when you open the door. If you live in a warm region, make sure that dry somatropin is not stored at temperatures above 40°C, and liquid somatropin – above 2°C-8°C. Keep the hormone away from direct sunlight.

Somatropin is transported to you by special methods that can prevent any negative consequences, such as falling or overheating. Growth hormone is transported in containers.

Duration of Growth Hormone Courses

Muscle gain, fat breakdown, rejuvenation and saturation of cells with amino acids, as well as general improvement of the body – these things happen gradually when administering growth hormone. That is why growth hormone is taken and prescribed in courses. The schedule is as follows: the injection period lasts two to seven (max) months and the recommended dose is 2 (women) and 5 (men) to 7 (women) and 15-20 (men) units of growth hormone per day.

We remind you that the use of somatropin must be started with small doses and increased gradually. However, if adverse effects appear, you should get in touch with your body. The most effective dose is 5 units, which can be injected not earlier than the second or third week of the course. Doses exceeding 10 units require the obligatory adding of maintenance drugs; for example insulin. There are many schedules of somatropin administration. For example, combination with testosterone increases muscle mass, and combination with thyroid hormones provides cutting. To avoid serious adverse effects, do not ignore the permissible doses, guidelines and duration of courses!

The post Transportation and Injection of Growth Hormone appeared first on Rexon Anabolics.

The point is that we live in a terrible environment: exhaust gases, rush of city life, and endless stress.

But who prevents us from looking the way we want ?

Pharmacodynamic properties of Genotropin by Pfizer

Genotropin contains somatropin, a human growth hormone, synthesized using DNA technologies.

Somatropin is a potent metabolic hormone of importance for the metabolism of lipids, carbohydrates and proteins.

In children with inadequate endogenous growth hormone, somatropin stimulates linear growth and increases growth rate.

In adults, as well as in children, somatropin maintains a normal body composition by increasing nitrogen retention and stimulation of skeletal muscle growth, and by mobilization of body fat.

Visceral adipose tissue is particularly responsive to somatropin.

In addition to enhanced lipolysis, somatropin decreases the uptake of triglycerides into adipose depots.

Serum concentrations of IGF-1 and IGFBP-3 (insulin-like growth factor binding protein 3) are increased by somatropin.

In addition, the following actions have been demonstrated:

Lipid metabolism: Somatropin induces hepatic LDL cholesterol receptors, and affects the profile of serum lipids and lipoproteins.

In general, administration of somatropin to growth hormone deficient patients results in reductions in serum LDL and apolipoprotein B.

A reduction in serum total cholesterol may also be observed.

Carbohydrate metabolism: Somatropin increases insulin, but fasting blood glucose is commonly unchanged.

Children with hypopituitarism may experience fasting hypoglycemia. This condition is reversed by somatropin. Water and mineral metabolism Growth hormone deficiency is associated with decreased plasma and extracellular volumes.

Both are rapidly increased after treatment with somatropin.

Somatropin induces the retention of sodium, potassium and phosphorus.

Bone metabolism Somatropin stimulates the bone turnover. Long-term administration of somatropin to growth hormone deficient patients with osteopenia results in an increase in bone mineral content and density.

Physical capacity: Muscle strength and physical exercise capacity are improved after treatment with somatropin.

Somatropin also increases cardiac output, but the mechanism has yet to be clarified.

A decrease in peripheral vascular resistance may contribute to this effect.

In clinical trials in short children born small for gestational age (SGA) doses of 0.033 and 0.067 mg/kg body weight per day have been used for treatment until final height.

In 56 patients who were continuously treated and have reached (near) final height, the mean change from height at start of treatment was +1.90 SDS (0.033 mg/kg body weight per day) and +2.19 SDS (0.067 mg/kg body weight per day).

Literature data from untreated SGA children without early spontaneous catch-up suggest a late growth of 0.5 SDS.

The data on the safety in long-term administration of the drug are still limited.

Pharmacokinetic properties Absorption The bioavailability of subcutaneously administered Genotropin is approximately 80 % in both healthy subjects and growth hormone deficient patients.

A subcutaneous dose of 0.035 mg/kg of somatropin results in plasma Cmax and tmax values in the range of 13-35 ng/ml and 3-6 hours, respectively.

Elimination The mean terminal half-life of Genotropin after IV administration in growth hormone deficient adults is about 0.4 hours.

However, after SC administration, half-life of 2-3 hours is achieved.

This difference is likely due to slow absorption from the injection site following SC administration. Sub-populations. The absolute bioavailability of somatropin seems to be similar in males and females following SC administration.

Information on the pharmacokinetics of somatropin in geriatric and pediatric populations, in different races and in patients with renal, hepatic or cardiac insufficiency is either lacking or incomplete.

Preclinical safety data In studies on general toxicity, local tolerance and reproduction toxicity no clinically relevant effects have been observed.

In vitro and in vivo, results of genotoxicity studies on gene mutations and induction of chromosome aberrations were negative.

An increased chromosome fragility has been observed in one in-vitro study on lymphocytes taken from patients after long-term treatment with somatropin and following the addition of the radiomimetic agent bleomycin.

The clinical significance of this finding is unclear. In another study, no increase in chromosomal abnormalities was found in the lymphocytes of patients who had received long-term somatropin therapy.

Therapeutic indications

Children Growth disturbance due to insufficient secretion of growth hormone (growth hormone deficiency, GHD); growth disturbance due to Shereshevsky-Turner syndrome; or growth disturbance during puberty due to chronic renal insufficiency we have described more in this article.

Growth disturbance (current height standard deviation score (SDS)  < – 2.5 and parental adjusted height SDS < – 1] in short children born small for gestational age (SGA), with a birth weight and/or length below <- 2 SD, who failed to show catch-up growth (height velocity SDS < 0 during the last year] by 4 years of age or later.

Growth disturbance due to Prader-Willi syndrome (PWS) for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.

For Adults Genotropin is indicated as a replacement therapy for adults with pronounced growth hormone deficiency associated with multiple hormone deficiencies as a result of known hypothalamic or pituitary pathology, and for patients who have at least one known deficiency of a pituitary hormone, except for prolactin.

These patients should undergo an appropriate dynamic test in order to diagnose or exclude a growth hormone deficiency.

Patients who were growth hormone deficient during childhood (as a result of congenital, genetic, acquired, or idiopathic causes) should be re-evaluated for growth hormone secretory capacity after completion of longitudinal growth.

In patients with a high likelihood for persistent GHD, an IGF-I SDS < – 2 without growth hormone treatment for at least 4 weeks should be considered sufficient evidence of GHD. All other patients will require IGF-I assay and one growth hormone stimulation test. 

Posology and method of administration: Genotropin Pfizer

The dosage and administration schedule should be individualized.

The injection should be given subcutaneously and the site varied to prevent lipoatrophy. Growth disturbance due to insufficient secretion of growth hormone in children: Generally a dose of 0.025 – 0.035 mg/kg body weight per day or 0.7 – 1.0 mg/m2 body surface area per day is recommended.

Even higher doses have been used.

Where childhood onset GHD persists into adolescence, treatment should be continued to achieve full somatic development (e.g. body composition, bone mass).

For monitoring, the attainment of a normal peak bone mass defined as a T score >– 1 (i.e. standardized to average adult peak bone mass measured by dual energy X-ray absorptiometry taking into account sex and ethnicity) is one of the therapeutic objectives during the transition period.

For dosing guidelines, see adult section below. Prader-Willi syndrome, for improvement of growth and body composition.

Generally, a dose of 0.035 mg/kg body weight per day or 1.0 mg/m2 body surface area per day is recommended.

Daily doses of 2.7 mg should not be exceeded.

Genotropin should not be used in children with a growth velocity of less than 1 cm per year and near closure of epiphyses.

Growth disturbance due to Shereshevsky-Turner syndrome: A dose of 0.045 – 0.050 mg/kg body weight per day or 1.4 mg/m2 body surface area per day is recommended.

Growth disturbance in chronic renal insufficiency: A dose of 1.4 mg/m2 body surface area per day (0.045 – 0.050 mg/kg body weight per day) is recommended. Higher doses can be needed, if growth velocity is too low.

A dose adjustment can be needed after six months of treatment.

Growth disturbance in short children born small for gestational age: A dose of 0.035 mg/kg body weight per day (1 mg/m2 body surface area per day) is usually recommended until final height is reached.

Treatment should be discontinued after the first year of treatment, if the height velocity SDS is below +1. Treatment should be discontinued, if height velocity is <2 cm/year and bone age is >14 years (girls) or >16 years (boys), corresponding to closure of the epiphyseal growth plates.

Dosage recommendations for pediatric patients

Indication Dose per day, mg/kg body weight.

Dose per day, mg/m2 body surface area Insufficient secretion of growth hormone in children 0.025-0.035 0.07-0.10 Prader-Willi syndrome 0.035 0.10 Shereshevsky – Turner syndrome 0.045-0.050 0.14 Chronic renal insufficiency 0.045-0.050 0.14 Growth disturbance in short children born small for gestational age 0.035 0.10.

Growth hormone deficient adult patients In patients who continue growth hormone therapy after childhood GHD, the recommended dose is 0.2–0.5 mg per day. The dose should be gradually increased or decreased according to individual patient needs as determined by the IGF-I concentration.

In patients with adult-onset GHD, therapy should start with a low dose, 0.15–0.3 mg per day.

The dose should be gradually increased according to individual patient needs as determined by the IGF-I concentration.

In both cases treatment goal should be IGF-I concentrations within 2 SDS from the age-corrected mean value.

Patients with normal IGF-I concentrations at the start of the treatment should use such a dose of Genotropin to reach an upper range of normal IGF-I level, but not exceeding 2 SDS.

Clinical response and adverse effects should also be used as guidance for dose titration.

It is recognised that there are patients with GHD who do not normalize IGF-I levels despite a good clinical response, and thus do not require dose escalation.

The maintenance dose seldom exceeds 1.0 mg per day.  Women may require higher doses than men, since men become hypersensitive to IGF-1 over time.

This means that there is a risk that women, especially those on oral estrogen replacement therapy are under-treated, while men are over-treated.

Therefore, the dose of Genotropin should be adjusted every 6 months.

As normal physiological growth hormone production decreases with age, the dose of Genotropin should be reduced.

The minimum effective dose should be used. In patients aged 60 years or above, therapy should start with a dose of 0.1–0.2 mg per day and should be slowly increased according to individual patient needs.

The minimum effective dose should be used. The maintenance dose in these patients seldom exceeds 0.5 mg per day. Introduction. Genotropin 36 IU is administered subcutaneously using the Genotropin Pen injection device.

After the cartridge is inserted into the device, the drug is diluted automatically. When diluting, do not shake the solution, because this can lead to denaturation of the active substances.

Visually inspect the reconstituted solution for injection before use. Use only a clear solution without visible particles.

To prevent lipoatrophy, it is necessary to change the injection site.

  
Contraindications: Genotropin Go quick

Genotropin must not be used when there is any evidence of activity of a tumor.

Anti-tumor therapy must be completed prior to starting growth hormone therapy.

Genotropin should not be used for growth promotion in children with closed epiphyses.

Patients with acute critical illness suffering from complications following open-heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory should not be treated with Genotropin.

Hypersensitivity to the active substance or to any of the excipients.

Overdose of Genotropin (Somatropin):

For each group, the frequency of adverse effects is ranked by severity. Patients with growth hormone deficiency are characterized by extracellular volume deficit.

When treatment with Genotropin is started, this deficit is rapidly corrected.

In adult patients, adverse effects related to fluid retention, such as edema peripheral, face edema, musculoskeletal stiffness, arthralgia, myalgia and paraesthesia are common.

In general, these adverse effects are mild to moderate, arise within the first months of treatment and resolved spontaneously or with dose reduction.

The incidence of these adverse effects is related to the administered dose, the age of patients, and possibly inversely related to the age of patients at the onset of growth hormone deficiency.

In children, such adverse effects are uncommon (≥1/1,000 to <1/100). Children may have transient skin reactions at the injection site.

There were single case reports on type 2 diabetes mellitus.

Rarely, benign intracranial hypertension develops. In adults, carpal tunnel syndrome may rarely be diagnosed. In some patients who were treated with Genotropin, the formation of antibodies to it was noted.

Their binding activity was low and not clinically significant at all.

There were reports on reduction of serum cortisol levels, possibly by affecting carrier proteins with somatropin or by increased hepatic clearance.

The clinical significance of this finding is unclear.

Despite this, GCS replacement therapy should be adjusted before starting treatment with Genotropin.

Leukemia has been reported in a small number of growth hormone deficient patients, some of whom have been treated with somatropin; however, the incidence of leukemia does not differ from that in children without growth hormone deficiency.

In the post-marketing experience, rare cases of sudden death have been reported in patients with Prader-Willi syndrome treated with somatropin, although no causal relationship has been demonstrated (here you can learn more).

System organ class Common ≥1/100 to <1/10 Uncommon ≥1/1,000 to <1/100 Rare ≥1/10,000 to <1/1,000 Very Rare <1/10,000 Neoplasms (benign and malignant).

Diagnosis and therapy with Genotropin should be initiated and monitored by physicians who are appropriately qualified and experienced in the diagnosis and management of diseases specified in the THERAPEUTIC INDICATIONS section.

Myositis is a very rare adverse event that may be related to the preservative m-cresol which is part of Genotropin.

In the case of myalgia or increased soreness at the injection site, myositis should be suspected.

If confirmed, a form of Genotropin without m-cresol should be used. Somatropin can cause insulin resistance and hyperglycemia in some patients, and therefore patients should be tested for a low glucose tolerance.

Sometimes the appearance of signs of type II diabetes mellitus may be a consequence of the use of somatropin, therefore it must be borne in mind that in most cases in diabetes mellitus there are risk factors such as obesity (including obesity in patients with Prader-Willi syndrome), family history, steroid therapy or a pre-existing low glucose tolerance.

In patients with diabetes mellitus, after the prescription of Genotropin, it may be necessary to correct antidiabetic therapy.

Somatropin increases the conversion of T4 to T3, which may result in a reduction in serum T4 and an increase in serum T3 concentrations.

Usually, the peripheral thyroid hormone levels have remained within the reference ranges, but hypothyroidism may develop in patients with subclinical hypothyroidism.

By contrast, in patients receiving thyroxine as a replacement therapy, moderate hyperthyroidism may develop.

In this regard, it is recommended to examine the thyroid gland after starting treatment with somatropin and after adjusting its dose.

In growth hormone deficiency secondary to treatment of malignant disease, it is recommended to pay attention to signs of relapse of the malignancy.

In patients with endocrine disorders, including growth hormone deficiency, slipped epiphyses of the hip may occur more frequently than in the general population.

Children limping during treatment with somatropin, should be examined clinically. In case of severe or recurrent headache, visual problems, nausea and/or vomiting, a funduscopy for papilledema is recommended.

If papilledema is confirmed, a diagnosis of benign intracranial hypertension should be considered. If necessary, growth hormone treatment should be discontinued.

At present, there is insufficient evidence to give specific advice on the continuation of growth hormone treatment in patients with clinical manifestations of intracranial hypertension.

However, clinical experience shows that the re-initiation of therapy in most cases did not cause an occurrence of signs of intracranial hypertension.

If growth hormone treatment is restarted, careful monitoring for symptoms of intracranial hypertension is necessary. Experience in the use of Genotropin in patients aged 80 years or above is limited.

Elderly patients may be more sensitive to the action of Genotropin, and therefore may be more prone to develop adverse reactions.

In patients with Prader-Willi syndrome, treatment should always be in combination with a calorie-restricted diet.

There have been reports of fatalities associated with the use of growth hormone in pediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity (those patients exceeding a weight/height ratio of 200%), history of respiratory failure or sleep apnea, or unidentified respiratory infection.

Patients with one or more of these factors may be at increased risk.

Before initiation of treatment with somatropin in patients with Prader-Willi syndrome, signs for upper airway obstruction, sleep apnea, or respiratory infections should be assessed.

If during the evaluation of upper airway obstruction, pathological findings are observed, the child should be referred to an Ear, nose and throat (ENT) specialist for treatment and resolution of the respiratory disorder prior to initiating growth hormone treatment.

Sleep apnea should be assessed before onset of growth hormone treatment by polysomnography or overnight oxymetry, and monitored if sleep apnea is suspected.

If during treatment with somatropin patients show signs of upper airway obstruction (including onset of or increased snoring), treatment should be interrupted, and a new ENT assessment performed.

All patients with Prader-Willi syndrome should be monitored, if sleep apnea is suspected. Patients should be monitored for signs of respiratory infections, which should be diagnosed as early as possible and treated aggressively.

All patients with Prader-Willi syndrome should also have effective weight control before and during growth hormone treatment.

Scoliosis is common in patients with Prader-Willi syndrome.  Scoliosis may progress in any child during rapid growth. Signs of scoliosis should be monitored during treatment.

The incidence and severity of scoliosis did not increase with the use of growth hormone.

Experience with long-term treatment in adults and in patients with Prader-Willi syndrome is limited. In short children born SGA, the reasons that could explain growth disturbance should be ruled out before starting treatment.

In SGA children, it is recommended to measure fasting insulin and blood glucose before start of treatment and annually thereafter. 

In patients with increased risk for diabetes mellitus (e.g. family history of diabetes, obesity, severe insulin resistance, or acanthosis nigricans) oral glucose tolerance testing (OGTT) should be performed. If diabetes is confirmed, growth hormone should not be administered. In SGA children, it is recommended to measure the IGF-I level before start of treatment and twice a year thereafter. 

If on repeated measurements IGF-I levels exceed +2 SD compared to references for age and pubertal status, the IGF-I / IGFBP-3 ratio could be taken into account to consider dose adjustment.

Experience in initiating treatment in SGA children near onset of puberty is limited.  It is therefore not recommended to initiate treatment near onset of puberty.

Experience in patients with Silver-Russell syndrome is limited. Sometimes, in early termination, the success of treatment in short SGA children before they reach their final height, may be lost. In chronic renal insufficiency, renal function should be below 50% of normal before starting the therapy of Genotropin.

To confirm growth disturbance, this parameter should be monitored for a year preceding institution of therapy.

During this period and treatment with somatropin, conservative treatment for renal insufficiency (which includes control of acidosis, hyperparathyroidism and nutritional status) should be continued.

The treatment should be discontinued at renal transplantation. To date, no data on final height in patients with chronic renal insufficiency treated with Genotropin are available.

The efficacy of Genotropin was studied in two placebo-controlled trials involving 522 critically-ill patients suffering from complications following open-heart surgery, abdominal surgery, multiple accidental trauma or acute respiratory failure.

Mortality was higher in patients treated with 16 or 24 IU (5.3 or 8 mg) of Genotropin daily compared to patients receiving placebo (41.9% and 19.3%, respectively).

Based on this information, this group of patients should not be treated with Genotropin.

For rationale of the use of Genotropin in patients developing other or similar acute critical illness, the possible benefit of treatment must be weighed against the potential risk.

Pregnancy and lactation. Clinical experience in pregnant women is limited. Animal studies are not finished yet. If pregnancy is diagnosed, the use of Genotropin should be discontinued.

During the course of normal pregnancy, the level of pituitary-derived growth hormone drops significantly after week 20 and is replaced almost completely by placental one by week 30.

Therefore, it is unlikely to continue growth hormone replacement therapy in the III trimester of pregnancy in women with deficiency.

It is not known whether peptide hormones are excreted in human milk, but absorption of intact protein from the gastrointestinal tract of the infant is extremely unlikely.

Children The drug is used in pediatric practice. Effects on ability to drive and use machines.

There were no signs of influence on the ability to drive and use machines.

Genotropin can increase the clearance of compounds metabolized by cytochrome P450 3A4 (e.g. sex steroids, corticosteroids, anticonvulsants and cyclosporine).

The clearance of compounds metabolized by cytochrome P 450 3A4 may be especially increased resulting in low plasma levels of these compounds.

The clinical significance of this effect is unknown.

Overdose and intoxication are not described. Acute overdose could lead initially to hypoglycemia and subsequently to hyperglycemia.

Therapy is symptomatic.

Long-term overdose could result in signs and symptoms consistent with the known effects of human growth hormone excess.

Storage conditions: Store in a dark place at a temperature of 2 to 8 °C.   The reconstituted solution may be stored at a temperature of 2 to 8 °C for 28 days.

The post Full Information of Genotropin Cartridge by Pfizer appeared first on Rexon Anabolics.

A while ago, Brazilian scientists lifted the curtain of secrecy and discovered that growth hormone, which stimulates the skeletal maturation and the bone linear growth, as well as helps to maintain tissues and organs throughout life, also acts directly on the brain. This happens to conserve body energy when a person is losing weight.

Growth hormone has been known for decades, but this discovery shows it does a lot more than was thought. It works as follows: large amounts of growth hormone are found in muscles and tissues.

The growth hormone receptors are involved in the growth metabolism, and development and progress of the human body. Recently, namely, in May of this year, scientists discovered that the brain is also full of growth hormone receptors. This is a completely new and unique breakthrough!

It has also been studied that growth hormone is not only involved in growth metabolism, but primarily affects the metabolic reactions that conserve energy when we are hungry or when we limit ourselves to nutrition – in other words, we are on a diet.

Based on above, the low growth hormone levels can lead to a variety of problems: weight gain, significant energy loss, decreased libido, decreased cognitive function; in addition to the above, a low flow of somatropin leads to a restless sleep, a general decrease in immunity, and most importantly – a lack of growth hormone reduces muscle mass or prevents it from gaining.

As mentioned earlier in many of our articles, growth hormone is a chemical substance produced in the human body. However, not always and not in large amounts. For example, the maximum amount of growth hormone is produced in infancy, and the minimum – in old age. That is why you lose your youth, looks, and your confidence “over the years”. So, let’s take the human body. What does it consist of? Roughly speaking, of skin, bones and muscles, right?

Let’s talk about muscles

Skeletal muscle makes up about 40% of the human body weight. Adequate muscle mass is critical to health, as muscles have several important functions: movement, breathing, heat conservation, internal organ protection, and glucose and fat metabolism. The muscle mass regulation is of interest to a diverse group of people.

Some people like strength athletes and bodybuilders are primarily interested in increasing muscle mass. Others are interested in preventing muscle loss. This is very important for frail elderly people, people with myopathies, cancer, sepsis, HIV/AIDS and other medical conditions, people with reduced mobility due to trauma, and astronauts.

The mechanisms that regulate the maintenance of muscle mass are extensively studied in the light of the importance of this tissue to health. In addition to the above types of people, muscle gain is also interesting for ordinary people who care about their health: they go to the gym and maintain a healthy and active lifestyle.

Muscle is a highly elastic tissue that can adapt to changing functional requirements. Increased load on the muscle leads to boost in muscle mass or hypertrophy, while low load or non-use results in a decrease in mass or atrophy.

Both exercise and nutrition are a key regulator of muscle mass. Hormonal factors are just as important as lifestyle, nutrition, and your baseline (height, weight, and metabolism). How does growth hormone affect a person who seeks to gain muscle mass and build the perfect body?

The fact is that many of our body’s processes directly depend on the body protein turnover. We remind you that growth hormone consists of 191 amino acids, rough translation: “of 191 types of protein compounds”.

Protein turnover is the continuous breakdown and synthesis of proteins with recycling of amino acids. In stable condition, the rate of protein breakdown is rather slow. And when using growth hormone especially genotropin, it increases many times.

That is why growth hormone can have not even one, but several amazing effects on your body at once. In addition to reducing body fat and muscle growth, it strengthens your bones and reduces the traumatic effects: the skin heals faster (and not only the skin).

Cholesterol drops, you have a lot of energy (due to metabolic processes), and even the skin rejuvenates. After all, the hormone acts gradually and efficiently, capturing every organ and every cell.

However, nothing can be gained without hard work in several stages. When using somatropin, what stages are? Firstly, it is definitely healthy sleep. Secondly, the physical activity and food having a lot of protein and vegetables (vegetables contain amino acids). Thirdly, do not abuse the growth hormone units! It is scientifically proven that the wrong dosage reduces the effect.

Well, you know what they say, ‘if you want to change, start with yourself’ or an even more appropriate phrase ‘if you don’t like what you get, change what you consume’. That is why, before taking growth hormone, it is necessary to establish many points that you may never paid attention to before.

And in this case, morning exercise is never yet revoked! As well as rest, of course – proper rest, or in general – its presence, only factors that are good for your body.

The post Effect of Growth Hormone on Body Composition appeared first on Rexon Anabolics.

What is allergic asthma?

Allergic asthma is an inflammatory condition that causes the airways to swell, making it difficult to breathe.

According to an international team of researchers, testosterone stimulates the development of male sexual characteristics and suppresses the production of the immune cell type, which causes allergic asthma.

The researchers found that higher testosterone levels in mice helped stop the production of immune cells called congenital lymphoid cells.

• ILC2 is found in the lungs, skin and other organs more you can check here.

These cells produce inflammatory proteins that can cause inflammation of the lungs and be damaged when exposed to common causes of allergic asthma such as pollen, dust mites, cigarette smoke and pet hair.

The results of the study are based on experiments performed on mice.

• “There is a very interesting clinical observation that women are more susceptible to the disease and develop more severe bronchial asthma than men, so we tried to understand why this happens,” said study leader Cyril Silet of the Walter and Eliza Hall Institute in Melbourne Australia.

• The full report you can check here.

• “Our research shows that high testosterone levels in men prevent them from developing allergic asthma,” Seylett says..

The post Testosterone can protect men from allergic asthma appeared first on Rexon Anabolics.